R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Jan

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Adjuvant Durvalumab in Resected Early-Stage NSCLC

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25

AACR Announces Fellows of the AACR Academy Class of 2026

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett Esophagus Esophageal Cancer